×
HUMIRA (adalimumab) INJECTION
https://www.humirapro.com/

Official health care professional site from AbbVie Inc. Find safety and prescribing information, including BOXED WARNING, for HUMIRA (adalimumab).

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
https://www.nejm.org/doi/full/10.1056/NEJMoa1905725
The New England Journal of Medicine; Sands,B.,et al

Sep 25th, 2019 - BACKGROUND Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking. METHODS In a phase 3b, double-blind, double-dummy, randomized trial conducted at 245 centers in 34 countries, we compared vedolizumab with adalimumab in adults with moderately to severely active ulcerative colitis to ...

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)
https://www.businesswire.com/news/home/20190723006033/en/FDA-Approves-Samsung-Bioepis-HADLIMA%E2%84%A2-adalimumab-bwwd

Jul 23rd, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis. Please see below the full indicatio...

Dosing | HUMIRA (adalimumab)
https://www.humiraconnect.com/psoriatic-arthritis/dosing

Jun 26th, 2019 - Dosing See Important Safety Information, including BOXED WARNING.

Top drugs and companies by sales in 2018
https://www.nature.com/articles/d41573-019-00049-0
Nature Reviews;

Mar 11th, 2019 - As AbbVie’s Humira (adalimumab) tops the biggest-selling drug list again in 2018, it is hard to see where any challenger might come from to snatch the autoimmune disorder therapy’s crown ahead of its patent expiry in 2023. With the exception of Boehringer Ingelheim, AbbVie’s legal team has successfully settled with companies wanting to launch biosimilar versions of this monoclonal antibody (mAb...

Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis
https://news.abbvie.com/news/upadacitinib-meets-all-primary-and-ranked-secondary-endpoints-including-superiority-versus-adalimumab-in-phase-3-study-in-rheumatoid-arthritis.htm

Apr 8th, 2018 - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-COMPARE clinical trial showing that after 12 weeks, upadacitinib (15 mg, once-daily) met the primary endpoints of ACR20a and clinical remissionb versus placebo.1 All ranked secondary endpoints were also achieved versus either placebo or adalimumab (40 mg eve...

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935619/
Rheumatology and Therapy; Nash,P.,et al

Mar 30th, 2018 - Introduction Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations. Methods Individual patient data from the FUTURE 2 RCT (secukinumab vs. placebo; N = 299) wer...

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696282/
Rheumatology and Therapy; Strand,V.,et al

Jul 30th, 2017 - The Phase III FUTURE I and II trials demonstrated the clinical efficacy of secukinumab in active psoriatic arthritis (PsA). In the absence of head-to-head trials, this study compared the clinical efficacy and cost effectiveness of adalimumab 40 mg versus secukinumab 150 and 300 mg for the treatment of active PsA.

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338946/
Open Access Rheumatology; D'Angelo,S.,et al

Mar 1st, 2017 - Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease with a broad clinical spectrum and variable course. It can involve musculoskeletal structures as well as skin, nails, eyes, and gut. The management of PsA has changed tremendously in the last decade, thanks to an earlier diagnosis, an advancement in pharmacological therapies, and a wider application of a multidisciplinary...

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in c...
https://doi.org/10.1016/S0140-6736(17)31189-3
Lancet (London, England); Papp K, Thaçi D et. al.

May 9th, 2017 - Adalimumab is indicated for the treatment of moderate to severe psoriasis in adults. We assessed the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis. This randomised, double-blind, multiperiod, phase 3 trial was done at 38 clinics in 13 countries. Patients (aged ≥4 to <18 years) with severe plaque psoriasis who had not responded to topical therapy were...

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
https://doi.org/10.1056/NEJMoa1905725
The New England Journal of Medicine; Sands BE, Peyrin-Biroulet L et. al.

Sep 25th, 2019 - Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking. In a phase 3b, double-blind, double-dummy, randomized trial conducted at 245 centers in 34 countries, we compared vedolizumab with adalimumab in adults with moderately to severely active ulcerative colitis to determine whether ve...

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
https://doi.org/10.1056/NEJMoa1504370
The New England Journal of Medicine; Kimball AB, Okun MM et. al.

Aug 15th, 2016 - Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy against hidradenitis suppurativa. PIONEER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppurativa, with two double-blind, placebo-controlled ...

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Inf...
https://doi.org/10.1053/j.gastro.2016.04.002
Gastroenterology Julsgaard M, Christensen LA et. al.

Apr 11th, 2016 - Little is known about in utero exposure to and postnatal clearance of anti-tumor necrosis factor (anti-TNF) agents in neonates. We investigated the concentrations of adalimumab and infliximab in umbilical cord blood of newborns and rates of clearance after birth, and how these correlated with drug concentrations in mothers at birth and risk of infection during the first year of life. We perform...

Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoi...
https://doi.org/10.1002/art.39399
Arthritis & Rheumatology (Hoboken, N.J.); Yun H, Xie F et. al.

Aug 31st, 2015 - The risks of hospitalized infection associated with biologic agents used to treat rheumatoid arthritis (RA) are unclear. The aim of this study was to determine whether the associated risk of hospitalized infections differed between specific biologic agents used to treat RA. In a retrospective cohort study using Medicare data from 2006-2011 for all enrolled patients with RA, new episodes of trea...

Biologic Treatment: How does HUMIRA work?
https://www.humirapro.com/rheumatology/how-humira-works

Learn about the mechanism of action of HUMIRA (adalimumab), and how it’s used for treatment of certain immune-mediated diseases.

ADEPT: A pivotal HUMIRA trial (N=313) in patients with active PsA who had an inadequate response to NSAIDs
https://www.humirapro.com/rheumatology/psoriatic-arthritis-clinical-data

ADEPT was a 24-week, randomized, double-blind, parallel-group, placebo-controlled study of 313 patients with active PsA (≥3 swollen joints and ≥3 tender joints) who had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). Patients were randomized to receive subcutaneous injections of either placebo (n=162) or 40 mg HUMIRA given every other week (n=151). Patients on methotrex...

Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197029
Annals of Internal Medicine; George MD, Baker JF et. al.

May 20th, 2019 - Patients with rheumatoid arthritis (RA) are at increased risk for infection after arthroplasty, yet risks of specific biologic medications are unknown. To compare risk for postoperative infection among biologics and to evaluate the risk associated with glucocorticoids. Retrospective cohort study. Medicare and Truven MarketScan administrative data from January 2006 through September 2015. Adults...

Treatment of nail psoriasis: best practice recommendations from the Medical Board of th...
https://doi.org/10.1001/jamadermatol.2014.2983
JAMA Dermatology; Crowley JJ, Weinberg JM et. al.

Dec 4th, 2014 - Nail psoriasis can be difficult to treat and has a significant effect on quality of life. Relatively few controlled trials evaluating treatments for nail psoriasis have been published. There is an unmet need for treatment recommendations to guide therapeutic decisions. To develop treatment recommendations for nail psoriasis from the Medical Board of the National Psoriasis Foundation. A PubMed s...

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883891
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association; Osterman MT, Haynes K et. al.

Jul 2nd, 2013 - Antibodies against tumor necrosis factor-α are widely used to treat patients with Crohn's disease (CD). This study compared the effectiveness of infliximab and adalimumab, the 2 most commonly used anti-tumor necrosis factor agents, in patients with CD. We conducted a retrospective cohort study by using U.S. Medicare data from 2006 through 2010. Patients with CD who were new users of infliximab ...